Revenue segments as reported by the company.

Smokeable Products

Oral Tobacco Products

Wine

All Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing, administration and research costs

Asset impairment and exit costs

Amortization of intangibles

General corporate expenses

Corporate asset impairment and exit costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Altria

Altria Group, Inc. operates as a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral tobacco products, and Wine. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral tobacco products segment is primarily moist smokeless tobacco products (MSTs) through brands like Copenhagen and Skoal as well as on! oral nicotine pouches sold by Helix. The Wine segment, through subsidiary Ste. Michelle Wine Estates Ltd, produces Washington State wines, primarily Chateau Ste. Michelle and 14 Hands, and owns wineries in or distributes wines from several other wine regions. The company was founded in 1919 and is headquartered in Richmond, VA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Altria reports robust Q4 earnings, focuses on innovation and growth

Altria's Q4 2022 performance reflects resilience amidst industry challenges, with a focus on innovation and shareholder returns. The company's strategic initiatives in smoke-free products and digital engagement underscore its commitment to long-term growth and harm reduction.

Altria reports resilient Q1 performance amid industry challenges and opportunities

Altria's Q1 2023 earnings call highlighted strong performance amidst industry challenges, emphasizing harm reduction and regulatory compliance. The company faces hurdles from inflation, regulatory changes, and evolving consumer behaviors, while focusing on growth opportunities in smoke-free products and strategic investments.

Altria reports solid Q2 earnings, eyes e-vapor growth opportunities

Altria's focus on smoke-free products and NJOY acquisition driving growth.
Challenges in the cigarette industry due to economic pressures and flavor bans.
Opportunities in the e-vapor category and expansion plans in the U.S.
Strong balance sheet and significant capital returns to shareholders.

Altria reports growth in earnings, navigates regulatory challenges in e-vapor

Altria's Q3 2023 earnings call highlighted solid financial performance, strategic focus on e-vapor products, and efforts to combat illegal vape products. The company faces challenges from regulatory uncertainties and illicit products but sees opportunities in expanding NJOY's reach and addressing market gaps.

Altria reports growth in smoke-free products amidst regulatory challenges

Altria's Q4 2023 earnings call highlighted growth in adjusted EPS, strategic focus on smoke-free products, and efforts to combat illicit e-vapor products. The company faces challenges in competitive segments and economic pressures but sees opportunities in new product introductions and regulatory collaborations.

Altria reports mixed Q1 performance, focuses on growth strategies

Altria's Q1 performance showed growth in NJOY and oral tobacco segments, with challenges in EPS decline and economic pressures on consumers.
Strengths include reaffirmed EPS guidance, strategic investments, and focus on combating illicit e-vapor products.
Opportunities lie in maximizing profitability in oral tobacco, product positioning, and capturing transitioning consumers.
Overall, Altria's performance reflects a mix of growth, challenges, and strategic opportunities in navigating market dynamics.

Altria's NJOY drives growth as company navigates e-vapor challenges

Altria's Q2 2024 earnings call showcased strong performance in smoke-free products, highlighting growth in retail share and volume momentum. Despite challenges in the e-vapor category, the company remains focused on responsible regulation and enforcement. With a commitment to shareholder value and long-term growth strategies, Altria is poised for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria Group, Inc. is a holding company, which engages in the manufacture and sale of cigarettes in the United States. It operates through the following segments: Smokeable Products, Oral Tobacco Products, and All Other. The Smokeable Products segment consists of cigarettes manufactured and sold by PM USA, and machine-made large cigars and pipe tobacco manufactured and sold by Middleton. The Oral Tobacco Products segment includes MST and snus products manufactured and sold by USSTC, and oral nicotine pouches manufactured and sold by Helix. The All Other segment refers to the financial results of NJOY, Helix ROW, and the IQOS System heated tobacco business. The company was founded in 1919 and is headquartered in Richmond, VA.

Altria Group, Inc. (MO) CEO Howard Willard on Q1 2019 Results - Earnings Call Transcript

Investors stub out Altria after its earnings miss.

Why Altria Stock Dropped 7%

Altria's (MO) Q1 performance hurt by high interest expenses as well as lower revenues in the smokeable segment.

Altria's (MO) Q1 Earnings Miss Estimates, High Interests Hurt

Altria Group Inc. reported first-quarter 2019 results before markets opened on Thursday morning.

Why Altria Earnings Went Up in Smoke

Altria on Thursday reported first-quarter earnings and revenue that missed analysts’ expectations.

Altria’s cannabis investment eats into first-quarter earnings, drives profit down 41%. Shares slide

Shares of Altria Group Inc.  dropped 2.6% in premarket trade Thursday, after the tobacco company reported first-quarter earnings and revenue that fell short of expectations.

Altria's stock drops after earnings, revenue fall more than expected

Fears of E-cigarette regulation and high debt levels are legitimate, but overblown.

Altria Fears Are Overblown

Altria (MO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Altria (MO) Ahead of Earnings?

Aurora Cannabis

Canopy Growth

Cronos Group

CannTrust Holdings

Constellation Brands

Shelf Offerings Could Cripple These 2 Pot Stocks in the Near Term

British American Tobacco

Philip Morris

Tobacco stocks fell Thursday, after Senate Majority Leader Mitch McConnell (Repub-Ky.) said he would introduce legislation that would raise the age to buy tobacco from 18 to 21.

Tobacco stocks move lower after Mitch McConnell unveils bill to raise legal age to 21 vs. 18

Altria's (MO) Q1 performance is likely to gain from RRPs and high pricing. However, receding cigarette sales are a concern.

Will Pricing & RRPs Aid Altria's (MO) Q1 Earnings Growth?

Altria (MO) closed at $56.43 in the latest trading session, marking a -0.9% move from the prior day.

Altria Stock Sinks As Market Gains

IMBBY vs. MO: Which Stock Is the Better Value Option?

IMBBY vs. MO: Which Stock Should Value Investors Buy Now?

A few dozen medical cases over nearly a decade launches a new probe into vaping.

FDA Sends New Scare Through E-Cig Industry

Altria has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Altria Keep the Earnings Surprise Streak Alive?

Which stock wins in a matchup between these two Canadian cannabis producers?

Better Marijuana Stock: Cronos Group vs. The Green Organic Dutchman

Altria (MO) closed the most recent trading day at $55.12, moving -0.29% from the previous trading session.

Altria (MO) Stock Moves -0.29%: What You Should Know

Altria provides information related to investment in JUUL to the FTC. It seeks to gain voting interests in JUUL.

Altria to Boost Interests in JUUL, Aims to Gain Voting Rights

Jim Cramer says if he had to pick a tobacco stock, he'd buy Altria as the company takes aggressive moves to offset the secular decline in smoking.

Cramer: Altria's non-tobacco moves makes it a compelling stock to buy

Tobacco stocks dipped Wednesday after the FDA announced it's investigating nearly three dozen cases of people experiencing seizures after vaping.

Tobacco stocks drop as FDA probes possible link between seizures and vaping

In the latest trading session, Altria closed at $57.74, marking a +0.54% move from the previous day.

Altria Gains But Lags Market: What You Should Know

The cannabis company's latest earnings report showed sluggish performance.

Was Cronos the Wrong Marijuana Stock for Altria?

The tobacco giant's decision to invest in marijuana grower Cronos Group appears to be paying off nicely despite early criticism.

Despite Cronos Group's Lull, Altria's Return on Investment Is Smoking Hot So Far

The tobacco titan gives investors many ways to win.

Is Altria Group a Buy?

Which of these consumer-goods giants is the smarter stock pick?

News for Altria Stock (MO)